Once-daily dosing in dogs optimizes daptomycin safety
- PMID: 11036005
- PMCID: PMC101585
- DOI: 10.1128/AAC.44.11.2948-2953.2000
Once-daily dosing in dogs optimizes daptomycin safety
Abstract
Daptomycin is a novel lipopeptide antibiotic with potent bactericidal activity against most clinically important gram-positive bacteria, including resistant strains. Daptomycin has been shown to have an effect on skeletal muscle. To guide the clinical dosing regimen with the potential for the least effect on skeletal muscle, two studies were conducted with dogs to compare the effects of repeated intravenous administration every 24 h versus every 8 h for 20 days. The data suggest that skeletal-muscle effects were more closely related to the dosing interval than to either the maximum concentration of the drug in plasma or the area under the concentration-time curve. Both increases in serum creatine phosphokinase activity and the incidence of myopathy observed at 25 mg/kg of body weight every 8 h were greater than those observed at 75 mg/kg every 24 h despite the lower maximum concentration of drug in plasma. Similarly, the effects observed at 25 mg/kg every 8 h were greater than those observed at 75 mg/kg every 24 h at approximately the same area under the concentration-time curve from 0 to 24 h. Once-daily administration appeared to minimize the potential for daptomycin-related skeletal-muscle effects, possibly by allowing for more time between doses for repair of subclinical effects. Thus, these studies with dogs suggest that once-daily dosing of daptomycin in humans should have the potential to minimize skeletal-muscle effects. In fact, interim results of ongoing clinical trials, which have focused on once-daily dosing, appear to be consistent with this conclusion.
Figures




Similar articles
-
Evaluation of Daptomycin-Induced Cellular Membrane Injury in Skeletal Muscle.Biol Pharm Bull. 2020 Sep 1;43(9):1338-1345. doi: 10.1248/bpb.b20-00217. Epub 2020 Jun 23. Biol Pharm Bull. 2020. PMID: 32581153
-
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9. doi: 10.1128/AAC.00247-06. Antimicrob Agents Chemother. 2006. PMID: 17005801 Free PMC article. Clinical Trial.
-
Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.Antimicrob Agents Chemother. 2003 Apr;47(4):1318-23. doi: 10.1128/AAC.47.4.1318-1323.2003. Antimicrob Agents Chemother. 2003. PMID: 12654665 Free PMC article. Clinical Trial.
-
Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review.J Antimicrob Chemother. 2018 Sep 1;73(9):2277-2283. doi: 10.1093/jac/dky072. J Antimicrob Chemother. 2018. PMID: 29547977 Free PMC article.
-
Daptomycin.Drugs. 2004;64(4):445-55; discussion 457-8. doi: 10.2165/00003495-200464040-00009. Drugs. 2004. PMID: 14969579 Review.
Cited by
-
Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients.Antimicrob Agents Chemother. 2015 Oct;59(10):6337-43. doi: 10.1128/AAC.01050-15. Epub 2015 Jul 27. Antimicrob Agents Chemother. 2015. PMID: 26248372 Free PMC article.
-
Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.Antimicrob Agents Chemother. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208714 Free PMC article.
-
Effect of daptomycin on primary rat muscle cell cultures in vitro.In Vitro Cell Dev Biol Anim. 2010 Jul;46(7):613-8. doi: 10.1007/s11626-010-9311-5. Epub 2010 Apr 10. In Vitro Cell Dev Biol Anim. 2010. PMID: 20383664
-
Daptomycin dose-effect relationship against resistant gram-positive organisms.Antimicrob Agents Chemother. 2003 May;47(5):1598-603. doi: 10.1128/AAC.47.5.1598-1603.2003. Antimicrob Agents Chemother. 2003. PMID: 12709328 Free PMC article.
-
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.Antimicrob Agents Chemother. 2010 Jul;54(7):2847-54. doi: 10.1128/AAC.01567-09. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439617 Free PMC article.
References
-
- Clarkson P, Nosaka K, Braun B. Muscle function after exercise-induced muscle damage and rapid adaptation. Med Sci Sports Exerc. 1992;24:512–520. - PubMed
-
- Hanberger H, Nilsson L E, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother. 1991;35:1710–1716. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical